| [1]Smith RE, Jr.The clinical and economic burden of anemia [J].Am J Manag Care, 2010, 16( Suppl Issues):S59-66[2]Li Y, Shi H, Wang WM, et al.Prevalence,awareness,and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter,cross-sectional study[J].Medicine (Baltimore), 2016, 95(24):e3872-e3880[3]张伟明，钱家麒.上海市透析登记及其结果分析[J].中国血液净化, 2012, 5:233-236[4]White Y, Grenyer BF.The biopsychosocial impact of end-stage renal disease: the experience of dialysis patients and their partners[J].J Adv Nurs, 1999, 30(6):1312-1320[5]Akizawa T, Pisoni RL, Akiba T, et al.Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS[J].Nephrol Dial Transplant, 2008, 23(11):3643-3653[6]Hirakata H, Tsubakihara Y, Gejyo F, et al.Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients[J].Clin Exp Nephrol, 2010, 14(1):28-35[7]Leaf DE, Goldfarb DS.Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia[J].Kidney Int, 2009, 75(1):15-24[8]Okpechi IG, Nthite T, Swanepoel CR.Health-related quality of life in patients on hemodialysis and peritoneal dialysis[J].Saudi J Kidney Dis Transpl, 2013, 24(3):519-526[9]Yamamoto T, Miyazaki M, Nakayama M, et al.Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages: the Gonryo study[J].Clin Exp Nephrol, 2016, 20(4):595-602[10]Iimori S, Naito S, Noda Y, et al.Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study[J].Nephrology (Carlton), 2015, 20(9):601-608[11]Inaba M, Hayashino Y, Shoji T, et al.Disappearance of association in diabetic patients on hemodialysis between anemia and mortality risk: the Japan dialysis outcomes and practice pattern study[J].Nephron Clinical practice, 2012, 120(2):c91-c100[12]Kuragano T, Matsumura O, Matsuda A, et al.Association between hemoglobin variability,serum ferritin levels,and adverse eventsmortality in maintenance hemodialysis patients[J].Kidney Int, 2014, 86(4):845-854[13]Drueke TB, Locatelli F, Clyne N, et al.Normalization of hemoglobin level in patients with chronic kidney disease and anemia[J].N Engl J Med, 2006, 355(20):2071-2084[14]Spinowitz B, Pecoits-Filho R, Winkelmayer WC, et al.Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review[J].J Med Econ, 2019, 22(6):593-604[15]左力，刘雪丽，韩晟.肾性贫血加重中国慢性肾脏病患者经济负担的研究[J].中国药物经济学, 2018, 13(9):11-16[16]茅雯辉，余学清，陈文.腹膜透析患者肾性贫血治疗的经济负担研究[J].中国卫生经济, 2012, 31(11):42-44[17]Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J.Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review[J].Ther Apher Dial, 2018, 22(5):444-456[18]Ibrahim HN, Ishani A, Guo H, Gilbertson DT.Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older[J].Nephrol Dial Transplant, 2009, 24(10):3138-3143[19]Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS.The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective[J].Dis Manag, 2008, 11(1):49-58[20]Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F.Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patientsSpanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology[J].J Am Soc Nephrol, 2000, 11(2):335-342[21]Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ.An economic evaluation of erythropoiesis-stimulating agents in CKD[J].Am J Kidney Dis, 2010, 56(6):1050-1061[22]Gupta N, Wish JB.Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD[J].Am J Kidney Dis, 2017, 69(6):815-826 |
